论文部分内容阅读
目的观察吉西他滨联合顺铂治疗耐蒽环类及紫杉类非小细胞肺癌的疗效及毒性反应。方法 48例对蒽环类及紫杉类耐药的非小细胞肺癌患者,接受吉西他滨1000mg/m2,静脉滴注,第1、8天;顺铂20mg/m2,静脉滴注,第1～5天;21天为1个周期。结果全组病例共完成192个周期,中位周期数为8个;6例完全缓解,28例部分缓解,10例病灶稳定,4例病灶进展,总有效率为68%。中位疾病进展时间为8个月,中位生存期为19个月;主要毒副反应为骨髓抑制及胃肠道反应。结论吉西他滨联合顺铂治疗耐蒽环类及紫杉类的非小细胞肺癌疗效较好,毒副反应较轻,可作为蒽环类及紫杉类治疗失败的非小细胞肺癌的解救方案。
Objective To observe the efficacy and toxicity of gemcitabine and cisplatin in the treatment of anthracycline and taxane non-small cell lung cancer. Methods Forty-eight patients with non-small cell lung cancer who were resistant to anthracyclines and taxanes received gemcitabine 1000 mg / m 2 intravenously on days 1 and 8, cisplatin 20 mg / m 2, intravenous drip, and 1 to 5 Day; 21 days for a cycle. Results A total of 192 cycles were completed in all patients. The median number of cycles was 8. Complete remission was achieved in 6, partial remission was achieved in 28, partial stabilization was achieved in 10, and progression was achieved in 4. The total effective rate was 68%. The median time to progression was 8 months, with a median survival of 19 months. The major toxicities were bone marrow suppression and gastrointestinal reactions. Conclusion The combination of gemcitabine and cisplatin in the treatment of anthracycline and taxane-resistant non-small cell lung cancer has good curative effect and mild side effects. It can be used as a rescue plan for non-small cell lung cancer with anthracycline and taxane failure.